Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer to Acquire Excaliard Pharmaceuticals | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pfizer to Acquire Excaliard Pharmaceuticals

Gains Phase II skin scarring drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer and Excaliard Pharmaceuticals, Inc. have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing drugs for the treatment of skin fibrosis. Excaliard will receive an upfront payment and related milestone payments. The acquisition is expected to close by the end of the year. Financial terms were not disclosed.

Excaliard’s lead product, EXC 001, is an antisense oligonucleotide currently in Phase II development and has the potential to reduce scar severity by inhibiting connective tissue growth factor (CTGF), which can be over expressed in damaged skin or tissue following surgery or traumatic injury. Pfizer plans to continue development of EXC 001 for excessive skin scarring, for which there are currently no FDA-approved products.

Jose-Carlos Gutierrez-Ramos, senior vice president, Biotherapeutics, Worldwide R&D, Pfizer, said, “The science behind Excaliard’s lead compound aligns well with our R&D focus on new treatments for fibrosis and tissue remodeling. We view EXC 001 as being well positioned to potentially become a novel, transformative therapy in a space with limited available treatment options.”

Gordon Foulkes, Excaliard’s chief executive officer, said, “We are all excited about Pfizer becoming the company to move our drug forward. We began Excaliard just four years ago with closing the Series A financing. Since that time, using a virtual organization and maximum outsourcing, we were able to move from lead generation to the completion of three Phase II trials. The whole team has just done a fantastic job.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters